Last reviewed · How we verify
Influenza vaccine, adjuvanted
Influenza vaccine, adjuvanted is a Vaccine Biologic drug developed by Arcturus Therapeutics, Inc.. It is currently in Phase 3 development for Influenza prevention in adults.
An adjuvanted influenza vaccine that enhances immune response through the addition of an adjuvant to improve antibody production and cellular immunity against influenza virus strains.
An adjuvanted influenza vaccine that enhances immune response through the addition of an adjuvant to improve antibody production and cellular immunity against influenza virus strains. Used for Influenza prevention in adults.
At a glance
| Generic name | Influenza vaccine, adjuvanted |
|---|---|
| Sponsor | Arcturus Therapeutics, Inc. |
| Drug class | Vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Adjuvanted influenza vaccines contain an immunological adjuvant that amplifies the body's innate immune response to the vaccine antigens, leading to stronger and more durable antibody responses and T-cell activation. This approach is particularly beneficial in populations with weaker immune responses, such as elderly individuals. The adjuvant works by activating pattern recognition receptors and enhancing antigen presentation to immune cells.
Approved indications
- Influenza prevention in adults
Common side effects
- Injection site pain or erythema
- Myalgia
- Fatigue
- Headache
- Fever
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- Estimate the Safety and Effectiveness of Adjuvanted Influenza Vaccine Among Asian Elderly People When Compared to Non-adjuvanted Vaccines (NA)
- Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients (PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- WU 345: Immune Responses to Adjuvanted and Non-adjuvanted Seasonal Influenza Vaccines in the Lymphoid Tissues. (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Influenza vaccine, adjuvanted CI brief — competitive landscape report
- Influenza vaccine, adjuvanted updates RSS · CI watch RSS
- Arcturus Therapeutics, Inc. portfolio CI
Frequently asked questions about Influenza vaccine, adjuvanted
What is Influenza vaccine, adjuvanted?
How does Influenza vaccine, adjuvanted work?
What is Influenza vaccine, adjuvanted used for?
Who makes Influenza vaccine, adjuvanted?
What drug class is Influenza vaccine, adjuvanted in?
What development phase is Influenza vaccine, adjuvanted in?
What are the side effects of Influenza vaccine, adjuvanted?
Related
- Drug class: All Vaccine drugs
- Manufacturer: Arcturus Therapeutics, Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Influenza prevention in adults
- Compare: Influenza vaccine, adjuvanted vs similar drugs
- Pricing: Influenza vaccine, adjuvanted cost, discount & access